BioAffinity Technologies, Ownership
| BIAF Stock | USD 0.29 0.01 3.57% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
BioAffinity |
BioAffinity Stock Ownership Analysis
About 30.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.6. Some equities with similar Price to Book (P/B) outperform the market in the long run. bioAffinity Technologies, recorded a loss per share of 0.91. The entity had not issued any dividends in recent years. bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. For more info on bioAffinity Technologies, please contact the company at 210 698 5334 or go to https://www.bioaffinitytech.com.Besides selling stocks to institutional investors, BioAffinity Technologies, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different BioAffinity Technologies,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align BioAffinity Technologies,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
BioAffinity Technologies, Quarterly Liabilities And Stockholders Equity |
|
About 30.0% of bioAffinity Technologies, are currently held by insiders. Unlike BioAffinity Technologies,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against BioAffinity Technologies,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of BioAffinity Technologies,'s insider trades
BioAffinity Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioAffinity Technologies, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading bioAffinity Technologies, backward and forwards among themselves. BioAffinity Technologies,'s institutional investor refers to the entity that pools money to purchase BioAffinity Technologies,'s securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-12-31 | 6.3 K | Oarsman Capital, Inc | 2024-12-31 | 2.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 500 | Clear Street Llc. | 2024-09-30 | 100.0 | Bank Of America Corp | 2024-12-31 | 84.0 | Jpmorgan Chase & Co | 2024-12-31 | 21.0 | Ground Swell Capital, Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-12-31 | 260.9 K | Geode Capital Management, Llc | 2024-12-31 | 99.6 K |
bioAffinity Technologies, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAffinity Technologies, insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAffinity Technologies,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioAffinity Technologies, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Currently Active Assets on Macroaxis
When determining whether bioAffinity Technologies, is a strong investment it is important to analyze BioAffinity Technologies,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies,'s future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 120.474 | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.